Notable absentees from the genes enriching in our CRISPR screens were the histone modifiers CREBBP, EP300, and KMT2D. These genes show very frequent inactivating mutations in DLBCL and follicular lymphoma40–43. This evidence concerns the gene KMT2D and diffuse large B-cell lymphoma.